文献速递肿瘤 PET/CT神经核医学

68Ga-DOTATATE PET/CT与18F-FDG PET/CT联合判读在转移性胃肠胰神经内分泌肿瘤中的预后分类系统

The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
PubMed 文献 · Clin Nucl Med · 2022-01-01

研究纳入87例转移性胃肠胰神经内分泌肿瘤患者,回顾性分析68Ga-DOTATATE与18F-FDG双示踪剂PET分类(D1、D2、D3三组)与无进展生存和总生存的关系。双示踪剂PET分类是总生存的独立预测因素(多变量P=0.016),也预测无进展生存(单变量P=0.030)。作者认为该分类系统与预后相关,需进一步前瞻性验证并探索其预测治疗反应的能力。

要点

  • 双示踪剂PET分类将转移性胃肠胰神经内分泌肿瘤分为D1、D2、D3三组。
  • 该分类是总生存的独立预测因素(多变量P=0.016),也预测无进展生存(单变量P=0.030)。
  • 嗜铬粒蛋白A和世界卫生组织分级也是总生存的独立预测因素。

核心结论

  • 结合68Ga-DOTATATE与18F-FDG PET复杂表现的双示踪剂分类系统与转移性胃肠胰神经内分泌肿瘤的预后相关。
  • 作者认为需进一步前瞻性研究验证这些发现,并探索双示踪剂PET评分是否也能预测治疗反应。

研究设计与样本

  • 回顾性评估87例转移性胃肠胰神经内分泌肿瘤患者,均有同时期68Ga-DOTATATE与18F-FDG PET检查。
  • 定义3个双示踪剂PET组:D1为68Ga-DOTATATE阳性/18F-FDG阴性,D2为68Ga-DOTATATE阳性/18F-FDG阳性,D3为68Ga-DOTATATE阴性/18F-FDG阳性。
  • 采用Kaplan-Meier分析评估双示踪剂PET分类与无进展生存和总生存的关联,并用Cox比例风险模型进行单变量和多变量分析。

主要发现

  • 双示踪剂PET分类是总生存的独立预测因素(多变量P=0.016),也预测无进展生存(单变量P=0.030)。
  • 总生存的其他独立预测因素包括嗜铬粒蛋白A和世界卫生组织分级。
  • 世界卫生组织分级与自双示踪剂PET检查起算的总生存无关,但却是自组织学诊断日起算的总生存的独立预测因素(多变量P=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步前瞻性研究验证这些发现,并探索双示踪剂PET评分是否也能预测治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) are widely heterogeneous in their biological behavior, and predicting prognosis and optimal treatment strategies can be challenging. 68Ga-DOTATATE PET/CT is a sensitive imaging modality for well-differentiated NEN and indicates a favorable prognosis, whereas 18F-FDG PET/CT avidity indicates disease that is potentially more aggressive. There has been emerging interest in the combined interpretation of 68Ga-DOTATATE and 18F-FDG PET and its prognostic significance. We aimed to assess the prognostic utility of a classification system that incorporates the complex findings of 68Ga-DOTATATE and 18F-FDG PET interpreted side-by-side in patients with metastatic GEP NEN. METHODS: We defined 3 68Ga-DOTATATE/18F-FDG "dual-tracer PET" groups: D1 (68Ga-DOTATATE positive/18F-FDG negative), D2 (68Ga-DOTATATE positive/18F-FDG positive), and D3 (68Ga-DOTATATE negative/18F-FDG positive). We retrospectively assessed the association between the dual-tracer PET classification and progression-free and overall survival (OS) using Kaplan-Meier analysis. Univariate and multivariate analyses were performed using the Cox proportional hazards model. RESULTS: Eighty-seven patients with metastatic GEP NEN and contemporaneous 68Ga-DOTATATE and 18F-FDG PET were included. The dual-tracer PET classification was an independent predictor of OS (multivariate P = 0.016) and also predicted progression-free survival (univariate P = 0.030). Other independent predictors of OS included chromogranin A and World Health Organization (WHO) grade. WHO grade was not associated with OS from the time of dual-tracer PET but was an independent predictor of OS from the date of histological diagnosis (multivariate P = 0.003). CONCLUSION: Our study demonstrates that a classification system combining the complex findings of 68Ga-DOTATATE and 18F-FDG PET is correlated with prognosis. Further research is needed to prospectively validate these findings and to explore whether dual-tracer PET scores may also be able to predict response to treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hayes AR, Furtado O'Mahony L, Quigley AM, et al. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact. Clin Nucl Med. 2022. PMID: 34874347. doi:10.1097/RLU.0000000000003937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。